SSY Group Ltd. is an investment holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company employs 5,700 full-time employees The company went IPO on 2005-12-20. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.
최신 재무제표(Form-10K)에 따르면, SSY Group Ltd의 총 자산은 $12,603이며, 순이익입니다.
LJUIF의 주요 재무 비율은 무엇인가요?
SSY Group Ltd의 유동비율은 2.34이고, 순이익률은 18.37, 주당 매출은 $1.94입니다.
SSY Group Ltd의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
SSY Group Ltd 주요 수익원은 Intravenous Infusion Solution and Others이며, 최신 수익 발표에서 수익은 5,585,094,000입니다. 지역별로는 China이 SSY Group Ltd의 주요 시장이며, 수익은 5,048,646,000입니다.